New
HealthMore in Health→
Neoadjuvant Durvalumab Strategy Guides Lung Cancer Treatment
Key Takeaways
- The phase 2 MDT-BRIDGE trial enrolled 142 people with resectable or borderline resectable NSCLC.
- The overall resection rate was 74.6%, while 92.3% received surgery or chemoradiotherapy after neoadjuvant treatment.
- The protocol used multidisciplinary reassessment to select surgery or chemoradiotherapy, followed by durvalumab where appropriate.
DE
DT Editorial Team··via nature.com
